$CDT Balance Sheet | Understand Stock

$CDT

$0.08 -$0.01 (14.89%) Close

$CDT Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021
ASSETS
Current assets
Cash
Prepaid expenses
Nonrelated Party
Related Party
Total prepaid expenses
Cash and cash equivalents
Marketable Investments
Digital assets
Prepaid R&D services- related party (see Note 8 and Note 13)
Prepaid R&D services (see Note 6)
Prepaid R&D services
Prepaid expenses and other current assets
Total current assets
Deferred offering costs
Prepaid expenses - noncurrent

Assets held-in-trust, noncurrent
Deferred offering costs
Intangible asset
Deposits and other long-term assets
Equity method investments
Operating lease right-of-use assets, net
Equipment and clinical assets, net
Prepaid expenses and other long-term assets
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accrued offering costs
Related party payable
Accrued expenses
Income taxes payable
Accrued excise tax
Accounts payable
Accrued professional fees
Accrued payroll
Option liability, current portion
Option liability
Investment payable
Accrued expenses and other current liabilities
Bank overdraft
Accrued litigation liability
Operating lease liability, current portion
Loans payable
Deferred commission payable
Convertible promissory note payable
Convertible promissory notes payable at fair value
Nonrelated Party
Related Party
Notes payable
Nonrelated Party
Related Party
Total notes payable
Total current liabilities

Convertible notes payable, carried at fair value
Liability related to the sale of future revenue
Notes payable
Option liability
Operating lease liability, non-current portion
Derivative warrant liability
Deferred commission payable
Total liabilities
Common stock subject to possible redemption at redemption value (2,187,728 shares at $10.56 per share and 13,225,000 shares at $10.34 per share, as of June 30, 2023 and December 31, 2022, respectively)
Stockholders’ equity (deficit)
Common stock, par value $0.0001; 250,000,000 shares authorized at June 30, 2026 and December 31, 2025, 631,080 shares and 9,214 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Common Class A
Common Class B
Total common stock, par value $0.0001; 250,000,000 shares authorized at June 30, 2026 and December 31, 2025, 631,080 shares and 9,214 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital
Treasury stock; 11,713 shares and nil shares issued at June 30, 2025 and December 31, 2024, respectively, at cost
Accumulated deficit
Accumulated other comprehensive income (loss)
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)

Comments